Company intelligence / Profile preview

Larimer Therapeutics

Philadelphia Area, Pennsylvania, United States

Ownership: Private
Employees: ~73
Development stage: Other

Overview

Larimar Therapeutics is advancing its lead candidate, nomlabofusp (formerly CTI-1601), for Friedreich’s ataxia. The product is a recombinant fusion protein designed to deliver human frataxin to mitochondria, aiming to address the root cause of the disease. Recent studies have shown positive top-line data for nomlabofusp in Phase 2 trials.

Therapeutic areas: Neurology
Modalities: Recombinant fusion proteinProtein replacement therapy
Industry: Biotech

Beyond the preview

Go deeper on Larimer Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Larimer Therapeutics.

Explore the full profile